论文部分内容阅读
目的探讨阿托伐他汀对治疗不稳定型心绞痛(UAP)的临床疗效。方法 60例UAP患者随机分成治疗组和对照组,对照组给予常规治疗,治疗组在常规治疗基础上+阿托伐他汀20 mg/d,疗程1 a。结果治疗组治疗后临床症状明显改善,TC、LDL-C及CRP降低,HDL升高,降低心血管事件(P均<0.05),治疗组疗效明显优于对照组,两组比较差异有统计学意义(P<0.05)。结论阿托伐他汀降低血脂及CRP,改善UAP患者临床症状,减少冠心病事件,不良反应少,故UAP早期调脂、抗炎治疗。
Objective To investigate the clinical efficacy of atorvastatin in the treatment of unstable angina pectoris (UAP). Methods Sixty UAP patients were randomly divided into treatment group and control group. The control group was given routine treatment. The treatment group received atorvastatin 20 mg daily for 1 year. Results After treatment, the clinical symptoms were significantly improved, TC, LDL-C and CRP were decreased, HDL was increased and cardiovascular events were decreased (all P <0.05). The curative effect of the treatment group was better than that of the control group. The difference between the two groups was statistically significant Significance (P <0.05). Conclusions Atorvastatin can reduce blood lipids and CRP, improve the clinical symptoms and reduce the incidence of coronary heart disease in UAP patients with less adverse reactions. Therefore, atorvastatin is an early lipid-lowering and anti-inflammatory therapy.